First fda approved immunotherapy to target LAG-3
Opdualag is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. nivolumab and relatlimab are produced in CHOcells.Both drugs are (ICIs) immune checkpoint inhibitors, which target proteins called checkpoints that help stop the immune system from mounting a […]